Skip to main content
. 2013 Nov 29;77(6):975–985. doi: 10.1111/bcp.12294

Table 1.

Socio-demographic characteristics and health habits of the participants at baseline according to randomization to the melatonin (CRM) or the placebo group, and statistical comparisons between the groups

CRM group (n = 46) Placebo group (n = 46) P
Median (IQR) [Range] Median (IQR) [Range]
Age (years) 66.5 (11) 65.0 (10) 0.959
[55–89] [56–91]
Body mass index (kg m–2) 27.3 (3.8) 26.4 (6.4) 0.312
[21.3–41.6] [18.8–37.1]
Doses of alcohol per week (1 dose = 12 g) 1.3 (5.5) [0–39.5] 1.1 (4) [0–13.3] 0.602
n (%) n (%)
Women 27 (59) 34 (74) 0.123
Exercise (h) in a week
<0.5 h 5 (11) 2 (4) 0.106
0.5–3 h 38 (83) 44 (96)
≥3 h 3 (6) 0 (0)
Smokers 6 (13) 1 (2) 0.111
Persons living alone 13 (28) 14 (30) 0.819
Education
Basic 22 (49) 18 (39) 0.607
Professional training 18 (40) 23 (50)
University or college 5 (11) 5 (11)
Occupation
Retired 37 (80) 36 (78) 0.854
Daytime work 6 (13) 8 (18)
Shift work 3 (7) 2 (4)
Persons having a driving licence 39 (85) 41 (89) 0.536
Duration of regular benzodiazepine use
<5 years 9 (20) 5 (11) 0.107
5–10 years 17 (37) 27 (59)
≥10 years 20 (43) 14 (30)
Range of use 2–26 years 1.5 months–35 years

IQR, interquartile range; P, Statistical significance of difference between CRM and placebo groups.